REMARKS

Reconsideration of this patent application is respectfully requested in view of the foregoing amendments, and the following remarks.

This will make of record the substance of the Telephone Interview on October 5, 2009, wherein the undersigned attorney pointed out to the Patent Examiner that the Restriction Requirement dated September 29, 2009, was directed to cancelled claims 1 to 24, rather than to pending claims 25 to 47. Thus, the Patent Examiner stated that he would withdraw the current Restriction Requirement and issue a new Supplemental Restriction Requirement.

The amendments to this patent application are to amend claim 25 to recite some additional features supported by claims 26 and 35.

On Page 3 of the Office Action, the Patent Examiner applied *Lestini* as a prior art reference. Hence, the Applicants comment upon this reference as follows.

Lestini et al describes liposomes for selective cell targeting in cardiovascular drug delivery. An RGD containing peptide is used as a model ligand to target liposomes to the integrin GPIIb-IIIa on activated platelets. Additionally,

oligodextran surfactants incorporated into liposomes provide insight into the effect of vesicle perturbations on liposome clearance. Fig. 2 shows the molecular schematic of a surface modified liposomal drug delivery vehicle for intravascular targeting. The liposome surface consists of a glycocalyx-like oligosaccharide layer to minimize non-specific interactions, and peptide ligands to mediate selective receptor targeting. An RGD peptide is coupled to the liposome through a poly(ethylene oxide) spacer.

Above mentioned claim 25 differs from *Lestini et al* by the polymerizable groups, which are incorporated in the hybrid particles.

This has the technical effect that a controlled release of micro-nutrients from the particles is obtained by cross-linking of the lipid layers in two dimensions through the polymerizable groups in the molecular structure of the hybrid particles. Polymerisation within the self-organised layers leads to stabilisation and can be used as a means of controlling the release of trapped micro-nutrients. The purpose of controlling the release of micro-nutrients is to ensure that specific micro-nutrients are not only concentrated in the target tissue but also remain constant in a high concentration over a longer period of time (page 11, last paragraph to page 12, first paragraph).

Lestini et al neither discloses the use of polymerizable

groups in the hybrid particle nor is it obvious to a person skilled in the art to include polymerizable groups.

For all the reasons set forth above, it is respectfully requested that the requirement for restriction be withdrawn, and that an action on the merits of all the claims be issued.

Respectfully submitted,
Jurgen BERNHARDT ET AL.

COLLARD & ROE, P.C.
1077 Northern Boulevard
Roslyn, New York 11576
(516) 365-9802

Edward R. Freedman, Reg.No.26,048
Frederick J. Dorchak, Reg.No.29,298
Attorneys for Applicants

ERF:lgh
Enclosures: Petition for 5 Month Extension of Time-Large Entity

I hereby certify that this correspondence is being deposited with the U.S. Postal Service as first class mail in an envelope addressed to: Commissioner of Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on March 26, 2010.

Amy Klein

R:\Patents\B\BERNHARDT ET AL - 2 PCT\amendment restriction requirement.wpd